Biogen illegally blocked generic Tecfidera, US antitrust complaint claims
MLex Summary: Biogen has been accused in US federal court of unlawfully impairing competition from generic versions of its brand-name prescription drug Tecfidera, which is used to treat multiple sclerosis. According...To view the full article, register now.
Already a subscriber? Click here to view full article